Abstract: The present invention provides a novel peptide that has an amino acid sequence represented by SEQ ID NO: 18, and binds to an active protease but does not bind to a pro-protease.

Abstract: The present invention provides sequence specific restriction enzymes for site-specific cleavage of RNA, as well as methods of their use.

Abstract: The present invention provides a glufosinate-ammonium dehydrogenase mutant and application in synthesis of L-glufosinate-ammonium thereof, the method uses 2-carbonyl-4-[(hydroxy)(methyl)phosphinoyl]-butyric acid or its salts as a substrate and the glufosinate-ammonium dehydrogenase or cells containing the glufosinate-ammonium dehydrogenase as a biocatalyst to carry out reductive amination, thereby obtaining L-glufosinate-ammonium. The method has features of high conversion rate of raw materials, high yield, easy separation and purification of the product, and high chiral purity; compared with other catalytic processes, the method in the present invention has features of relatively simple process and a conversion rate of raw materials up to 100%.

Abstract: The present invention relates to an in vitro or in vivo process for producing a glucuronide comprising a glucuronic acid moiety bound to a phenolic hydroxyl group or a phenolic carboxyl group. Also provided are expression vectors, nucleic acids, polypeptides, and recombinant microbial cells useful in carrying out the process and prodrugs produced by the process.

Abstract: An NADPH-regeneration system based on monomeric isocitrate dehydrogenase (IDH) and a use thereof. Specifically, the present invention relates to a recombinant vector including a polynucleotide encoding an isocitrate dehydrogenase recombinant protein derived from Corynebacterium glutamicum (CgIDH) and an isocitrate dehydrogenase recombinant protein derived from Azotobacter vinelandii (AvIDH), a method for producing the recombinant protein, and an NADPH-regeneration system using the recombinant protein produced by the method. The enzyme in a monomeric form that may be efficiently used in the NADPH-regeneration system in the transformant into which the recombinant vector was introduced, was found, and the NADPH-regeneration system using the enzyme in a monomeric form has a very high utility value as biological parts and biocatalyst materials that provides NADPH to the NADPH-dependent enzyme.

Abstract: The present disclosure encompasses engineered meganucleases that bind and cleave recognition sequences within a dystrophin gene. The present disclosure also encompasses methods of using such engineered meganucleases to make genetically modified cells. Further, the disclosure encompasses pharmaceutical compositions comprising engineered meganuclease proteins, or polynucleotides encoding engineered meganucleases of the disclosure, and the use of such compositions for the modification of a dystrophin gene in a subject, or for treatment of Duchenne Muscular Dystrophy.

Abstract: Provided is a microorganism that is able to produce 2-phenylethanol at a high concentration, and a method of efficiently producing 2-phenylethanol by using a saccharide as a raw material. Provided is a coryneform bacterium transformant in which a shikimate pathway is activated, and further, a gene that encodes an enzyme having phenylpyruvate decarboxylase activity is introduced in such a manner that the gene can be expressed. Also provided is a 2-phenylethanol producing method that includes causing the coryneform bacterium transformant according to the present disclosure to react in water containing a saccharide.

Abstract: Provided are amino acid sequences of ketoreductase polypeptides that are useful for asymmetrically synthesizing chiral alcohol compounds, its preparation process as well as reaction process under industrial-relevant conditions. Also provided are polynucleotide sequences encoding engineered ketoreductase polypeptides, engineered host cells capable of expressing engineered ketoreductase polypeptides, and methods of producing chiral alcohol compounds using engineered ketoreductase polypeptides. Compared to other enzymes, the engineered ketoreductase polypeptides provided by the invention have better catalytic activity and thermal stability, allowing purification of the enzyme solution by heat treatment, which is advantageous for the production of enzymes and the industrial application of enzymatic reactions.

Abstract: The present disclosure encompasses engineered meganucleases that bind and cleave recognition sequences within a dystrophin gene. The present disclosure also encompasses methods of using such engineered meganucleases to make genetically modified cells. Further, the disclosure encompasses pharmaceutical compositions comprising engineered meganuclease proteins, or polynucleotides encoding engineered meganucleases of the disclosure, and the use of such compositions for the modification of a dystrophin gene in a subject, or for treatment of Duchenne Muscular Dystrophy.

Abstract: The present disclosure relates, according to some embodiments, to systems, apparatus, compositions, methods, and workflows that include DNase I variants with desirable properties including, for example, salt tolerance. A DNase I variant, in some embodiments, may have an amino acid sequence that is at least 85% identical, at least 90% identical, at least 95% identical, and/or at least 98% identical to SEQ ID NO:1 and may be identical to SEQ ID NO:1 at one or more positions selected from the group of positions corresponding to L29, A35, D87, Q88, S94, P103, T108, P121, P132, A135, D145, E161, G172, P190, H208, and A224 of SEQ ID NO:1.

Abstract: Compositions and methods comprising novel deaminase polypeptides for targeted editing of nucleic acids are provided. Compositions comprise deaminase polypeptides. Also provided are fusion proteins comprising a DNA-binding polypeptide and a deaminase of the invention. The fusion proteins include RNA-guided nucleases fused to deaminases, optionally in complex with guide RNAs. Compositions also include nucleic acid molecules encoding the deaminases or the fusion proteins. Vectors and host cells comprising the nucleic acid molecules encoding the deaminases or the fusion proteins are also provided.

Abstract: The present invention relates to a recombinant microorganism imparted with increased ability to produce glutaric acid by further introducing a gene encoding a polypeptide having glutaric acid transporter activity into a microorganism having ability to produce glutaric acid, and to a method of preparing glutaric acid using the recombinant microorganism. According to the present invention, glutaric acid used for the preparation of various compounds such as polyamide, polyurethane, 1,5-pentanediol, and 5-hydroxyvaleric acid can be biosynthesized at high yield.

Abstract: Provided are a fusion protein comprising a Pab1 element and an eIF4G element and a preparation method therefor. The fusion protein can improve in-vitro translation efficiency. A constitutive or inducible promoter (for example, pKlPGK1) may also be inserted in front of eIF4G in the fusion protein for increasing in-vitro protein synthesis ability.

Abstract: A method for producing 2-keto-3-deoxygluconate (KDG) from 2-(acetylamino)-2-deoxy-D-gluconic acid (GlcNAc1A) by two enzymes; GlcNAc1A is converted to KDG by incubating GlcNAc1A with a deacetylase OngB at 25° C. for 4-12 h and then with a deaminase OngC at 25° C. for another 10-15 h; it constructs two engineered E. coli/pET22b-ongB (carrying the ongB gene) and E. coli/pET22b-ongC (carrying the ongC gene) strains to prepare recombinant proteins OngB and OngC, respectively; at the action of these two enzymes, OngB and OngC, GlcNAc1A is converted to KDG, which solves the bottleneck of GlcNAc1A utilization during the bioconversion of chitin; the KDG is an important metabolic intermediate to synthesize furan derivatives, herbicides, food additives and other industrially important chemical compounds, having wide industrial applications.

Abstract: The present invention provides a novel peptide that has an amino acid sequence represented by SEQ ID NO: 18, and binds to an active protease but does not bind to a pro-protease.

Abstract: Provided is an application of trehalase in fermentative production. The trehalase has amino acid sequences shown in SEQ ID NO.6, SEQ ID NO.7, and SEQ ID NO.8. Provided are methods for producing and applying trehalase, particularly being applied in the production and fermentation of alcohol and an amino acid.

Abstract: Disclosed are a recombinant acid-resistant yeast having improved lactic-acid-producing ability and a method of preparing lactic acid using the same. When producing lactic acid using the recombinant acid-resistant yeast according to the present invention, not only lactic-acid fermentation can be performed with lactic-acid-producing ability similar to that of bacterial fermentation using a remarkably smaller amount of a neutralizing agent than in the case of conventional bacterial fermentation, but also the production of ethanol and glycerol which are byproducts can be reduced. Thus, fermentation costs can be greatly reduced and the cost of subsequent purification processes can be reduced.

Abstract: Artificial lipoproteins bearing non-canonical post-translational modifications that are synthesized by leveraging substrate promiscuity of an acyltransferase. The non-canonical functionality of these lipoprotein results in a distinctive hysteretic assembly that is absent from the canonical lipoproteins and is used to prepare hybrid multiblock materials with precise and programmable patterns of amphiphilicity due to the unique assembly and function of the non-canonical post-translational modifications.

Abstract: The present disclosure provides engineered human extracellular DNASE proteins (e.g., variants of DNASE1 (D1), DNASE1-LIKE 1 (D1L1), DNASE1-LIKE 2 (D1L2), DNASE1-LIKE 3 Isoform 1 (D1L3), DNASE1-LIKE 3 Isoform 2 (D1L3-2), DNASE2A (D2A), and DNASE2B (D2B)) that are useful for treating conditions characterized by neutrophil extracellular trap (NET) accumulation and/or release. In accordance with the invention, the DNase variant has advantages for therapy and/or large-scale manufacturing.

Abstract: Provided herein are compositions, systems, and methods comprising effector proteins and uses thereof. These effector proteins are shown to be active with guide RNAs and may be characterized as CRISPR-associated (Cas) proteins. Various compositions, systems, and methods of the present disclosure leverage the activities of these effector proteins for the modification, detection, and engineering of nucleic acids.